.jetcityimage/iStock Content via Getty Images Morgan Stanley has picked Eli Lilly (NYSE: LLY) as its leading biopharma choice for 2025 and measured yet another 9 labels in the space as obese. The investment bank stated in a keep in mind that it continues to think “diabesity is readied to become.